In a recent study researchers examined transplant outcomes in patients with lupus nephritis who had no clinical evidence of disease in the year prior.
Genetic changes may partly explain why African-Americans with lupus are up to five times more likely develop end-stage kidney disease.
With systemic lupus erythematosus, kidney disease reduces life expectancy an average of 15 years
Predictors of moderate-severe SLE flare at week 52 identified using three indicators
A 50% or greater reduction in proteinuria after six months of treatment for severe lupus nephritis predicted better 15-year renal survival.
Lupus nephritis patients can be good candidates if their disease is quiescent for at least one year prior to surgery.
SLE patients with renal failure often continue to experience flares, but most commonly these are serologic rather than clinical.
If a lupus patient has never had renal disease, pregnancy, in and of itself, is not likely to increase that risk.
Even partial recovery in lupus nephritis patients lowers the risk of needing dialysis or a kidney transplant.
Effects of MMF may be influenced by the pathogenesis and/or cellular micro-environments unique to each disease process.
The American College of Rheumatology (ACR) has issued new guidelines for screening, treating, and managing lupus nephritis (LN), including methods of identifying kidney disease, newer therapies, and pregnant patient care.
Adding rituximab to mycophenolate mofetil and corticosteroids does not improve outcomes in patients with lupus nephritis (LN), according to a study.
Black race is associated with worse renal transplant outcomes among patients with lupus nephritis and focal segmental glomerulosclerosis (FSGS), according to two studies presented at Kidney Week, the annual meeting of the American Society of Nephrology.
Mycophenolate mofetil (MMF) is more effective than azathioprine as maintenance therapy for patients with active lupus nephritis (LN) who responded to induction therapy, researchers reported.
CHICAGO—Adding abatacept to mycophenolate mofetil (MMF) and steroids does not significantly improve the time to complete renal response in patients with lupus nephritis (LN), according to the findings of a 12-month study presented at the 2011 American College of Rheumatology annual meeting.
CHICAGO—Vascular biomarkers may forecast impending flare or flare outcome in patients with lupus nephritis (LN), according to researchers in New York.
CHICAGO—Certain features at the time of renal biopsy are associated with a particular class of lupus nephritis (LN) and may independently predict good renal outcomes, according to a new Canadian study presented at the 2011 American College of Rheumatology Annual Scientific Meeting.